Seres Therapeutics reported a net loss of $15.3 million for the fourth quarter of 2025, translating to a loss per share of $1.76. For the full year, the company posted a net loss of $5.7 million on revenue of $0.8 million, largely driven by grant income. The results include a $27.2 million gain from the sale of its VOWST business, which is excluded from continuing operations. Cash and cash equivalents stood at $45.8 million as of December 31 2025, giving the company a runway to fund operations through the third quarter of 2026.
The VOWST sale, completed in September 2024 to Nestlé Health Science, generated the $27.2 million gain recognized in 2025. The transaction was a one‑time event and is excluded from continuing operations, underscoring that the company’s core business remains focused on its live‑biotherapeutic pipeline.
Compared with 2024, when Seres posted a net loss of $125.8 million, the 2025 loss represents a dramatic improvement, driven in part by the VOWST sale and by cost‑cutting measures. Revenue of $0.8 million in 2025 is largely grant revenue, reflecting the company’s current lack of commercial sales.
Richard Kender, Executive Chair and interim CEO, said, “As highlighted in our recent announcements, we are prioritizing our promising inflammatory and immunology biotherapeutics portfolio, including SER‑603 for inflammatory bowel disease.” He added, “We are on track to report clinical data from the fully enrolled investigator‑sponsored study at Memorial Sloan Kettering Cancer Center evaluating SER‑155 to treat immune checkpoint inhibitor‑related enterocolitis in the second quarter of this year.” Kender also noted, “This serious condition affects up to 50% of immune checkpoint‑treated cancer patients, with rates varying based on cancer drug and treatment regimen, and represents a sizable therapeutic and commercial opportunity.” He further explained, “Additionally, our SER‑155 program for the prevention of serious bloodstream infections in patients undergoing allo‑HSCT for blood cancer is Phase 2 ready, and we continue to seek funding to support further development.” Finally, Kender said, “To advance these opportunities, we continue to judiciously manage our resources, focusing on progressing our prioritized programs, as we pursue partnerships and other funding sources.”
In September 2025, Seres reduced its workforce by roughly 25% to conserve cash. The company’s cash balance of $45.8 million, while sufficient for the next nine months, has prompted a “going concern” warning in recent filings, highlighting the urgency of securing additional capital.
The earnings report underscores Seres’ strategic pivot away from its legacy VOWST business toward a focused pipeline of live‑biotherapeutic candidates. While the company’s financials have improved, the limited cash runway and the need for external funding remain critical risks that could shape the company’s trajectory in the coming quarters.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.